Time delay to thrombolytic therapy

Time delay to thrombolytic therapy--a Sri Lankan perspective.

Reducing the time delay in initiating thrombolytic therapy in acute myocardial infarction is critical in maximising the functional and survival benefit. We analysed 120 consecutive admissions for thrombolytic therapy to the Coronary Care Unit. The total delay was divided into prehospital, in-hospital and Coronary Care Unit stages, and the median delays were found to be 130, 70, and 15 minutes, ...

New approaches to thrombolytic therapy.

Tissue-type plasminogen activator (t-PA), purified from the culture fluid of a stable human melanoma cell line, is a serine protease, different from urokinase, with a molecular weight of about 70,000. It is composed of one polypeptide chain, which is converted to a two-chain molecule by limited plasmic action. Activation of plasminogen to plasmin occurs by cleavage of the Arg 560-Val 561 peptid...

Thrombolytic therapy.

Thrombolytic therapy, which involves the administration of agents designed to increase fibrinolytic capacity, has been utilized in respiratory medicine for more than 50 years. A variety of agents have been used to effect thrombolysis, including urokinase plasminogen activator (uPA) and streptokinase. Tissue plasminogen activator (tPA) has also been used to effect thrombolysis. Both uPA and tPA ...

Thrombolytic Therapy.

The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...

[Thrombolytic therapy].